Publications by authors named "Anne M O'Broin Lennon"
A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising From Pancreatic Cysts.
Ann Surg
October 2023
Article Synopsis
- The study developed a new DNA/RNA next-generation sequencing platform called PancreaSeq Genomic Classifier to enhance the evaluation of pancreatic cysts, particularly in identifying cystic precursor neoplasms and advanced neoplasia.
- This platform features a 74-gene targeted NGS panel that assesses various genomic alterations, and it was validated in separate cohorts, demonstrating high sensitivity and specificity for diagnosing pancreatic conditions.
- The results show that PancreaSeq significantly increased the sensitivity of traditional pancreatic cyst guidelines by over 10% while maintaining high specificity, indicating its potential to improve clinical decision-making.
Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts.
Gastroenterology
January 2023
Article Synopsis
- This study aimed to prospectively evaluate the effectiveness of next-generation sequencing (NGS) on pancreatic cyst fluid in a multi-institutional setting, as previous research had mainly been retrospective or focused on single hospitals.
- In total, 1933 pancreatic cyst specimens were tested, with 98% being satisfactory for NGS analysis, and findings were correlated with current guidelines and surgical outcomes.
- Results indicated that mutations such as GNAS had high sensitivity and specificity for diagnosing mucinous cysts and that combining genomic alterations with cytopathologic evaluation significantly improved diagnostic accuracy compared to existing guidelines.
Background: The aim of this study was to determine the incidence of high-grade dysplasia (HGD) or invasive carcinoma in patients with small branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).
Methods: 923 patients who underwent surgical resection for an IPMN were identified. Sendai-negative patients were identified as those without history of pancreatitis or jaundice, main pancreatic duct size (MPD) <5 mm, cyst size <3 cm, no mural nodules, negative cyst fluid cytology for adenocarcinoma, or serum carbohydrate antigen 19-9 (CA 19-9) <37 U/L.
Background Incidental detection of pancreatic cystic neoplasm (PCN) has increased. Since a small percentage of PCNs possess malignant potential, management is challenging. The recently revised American College of Radiology (ACR) recommendations define PCN measurement and growth for different categories based on baseline cyst size.
View Article and Find Full Text PDFObjectives: To evaluate the added value of diffusion-weighted imaging (DWI) on MRI in differentiating serous from mucin-producing pancreatic cystic neoplasms (PCNs).
Methods: One hundred seventeen patients with PCN measuring ≥ 10 mm were included. Three readers independently evaluated MRI with and without the use of apparent diffusion coefficient (ADC).
Objectives: To assess reproducibility of volume and diameter measurement of intraductal papillary mucinous neoplasms (IPMNs) on MRI images.
Methods: Three readers measured the diameters and volumes of 164 IPMNs on axial T2-weighted images and coronal thin-slice navigator heavily T2-weighted images using manual and semiautomatic techniques. Interobserver reproducibility and variability were assessed.
Objectives: To evaluate and compare the accuracy of absolute apparent diffusion coefficient (ADC) and normalised ADC (lesion-to-spleen ADC ratio) in differentiating pancreatic neuroendocrine tumour (NET) from intrapancreatic accessory spleen (IPAS).
Methods: Study included 62 patients with the diagnosis of pancreatic NET (n=51) or IPAS (n=11). Two independent reviewers measured ADC on all lesions and spleen.
Objective: To determine the feasibility of genotyping pancreatic tumors via fine needle aspirates (FNAs).
Background: FNA is a common method of diagnosis for pancreatic cancer, yet it has traditionally been considered inadequate for molecular studies due to the limited quantity of DNA derived from FNA specimens and tumor heterogeneity.
Methods: In vitro mixing studies were performed to deduce the minimum cellularity needed for genetic analysis.